Alvotech (OISE:ALVO) Change In Payables And Accrued Expense : kr2,948 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Alvotech Change In Payables And Accrued Expense?

Alvotech's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was kr-3,976 Mil. It means Alvotech's Accounts Payable & Accrued Expense declined by kr3,976 Mil from Dec. 2023 to Mar. 2024 .

Alvotech's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was kr4,367 Mil. It means Alvotech's Accounts Payable & Accrued Expense increased by kr4,367 Mil from Dec. 2022 to Dec. 2023 .

Alvotech Change In Payables And Accrued Expense Historical Data

The historical data trend for Alvotech's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alvotech Change In Payables And Accrued Expense Chart

Alvotech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

270.50

31.20

1,968.01

2,259.96

4,367.07

Alvotech Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial									-2,556.58	1,706.86	771.92	4,444.87	-3,976.03

Alvotech Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2,948 Mil.

Alvotech Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Alvotech's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Alvotech (OISE:ALVO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alvotech (OISE:ALVO) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

ALVO:USA Z45:Germany

Address

9, rue de Bitbourg, Luxembourg, LUX, L-1273

Website

https://www.alvotech.com

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.